| 000 | 01372 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515044553.0 | ||
| 264 | 0 | _c20070406 | |
| 008 | 200704s 0 0 eng d | ||
| 022 | _a1053-8569 | ||
| 024 | 7 |
_a10.1002/pds.1341 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMcClure, David L | |
| 245 | 0 | 0 |
_aSystematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. _h[electronic resource] |
| 260 |
_bPharmacoepidemiology and drug safety _cFeb 2007 |
||
| 300 |
_a132-43 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aMuscular Diseases _xchemically induced |
| 650 | 0 | 4 |
_aMyositis _xchemically induced |
| 650 | 0 | 4 | _aOdds Ratio |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xmethods |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 |
_aRhabdomyolysis _xchemically induced |
| 650 | 0 | 4 | _aRisk Assessment |
| 700 | 1 | _aValuck, Robert J | |
| 700 | 1 | _aGlanz, Morton | |
| 700 | 1 | _aHokanson, John E | |
| 773 | 0 |
_tPharmacoepidemiology and drug safety _gvol. 16 _gno. 2 _gp. 132-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/pds.1341 _zAvailable from publisher's website |
| 999 |
_c16647188 _d16647188 |
||